Company intelligence / Profile preview
Glysantis Inc.
Canadaglysantis.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Glysantis Inc. develops nano-enabled immunomodulatory therapeutics targeting the innate immune system, with a focus on cancer treatment. Their lead program, GLY‑100, uses a phytoglycogen nanoparticle platform to deliver oligonucleotide drugs and has shown promise in preclinical models for ovarian adenocarcinoma. The company collaborates with major academic institutions but has not yet advanced any candidates into clinical trials as of early 2025.
- Therapeutic areas
- OncologyEndocrinology
- Modalities
- Oligonucleotides (dsRNA)Nanoparticles
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Academic collaborations with University of GuelphWilfrid Laurier UniversityUniversity of WashingtonHarvard University
Beyond the preview
Go deeper on Glysantis Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Glysantis Inc..